Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 12,837 Shares

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 12,837 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total transaction of $290,886.42. Following the transaction, the chief executive officer directly owned 581,450 shares of the company’s stock, valued at $13,175,657. The trade was a 2.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total transaction of $619,552.52.

Heartflow Trading Down 0.6%

NASDAQ:HTFL traded down $0.12 during mid-day trading on Friday, hitting $20.68. The company’s stock had a trading volume of 441,490 shares, compared to its average volume of 1,396,040. The company has a market capitalization of $1.76 billion and a price-to-earnings ratio of -11.41. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22. The stock has a fifty day moving average of $27.83 and a 200-day moving average of $30.76.

Institutional Investors Weigh In On Heartflow

Hedge funds and other institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. bought a new stake in shares of Heartflow during the third quarter worth $101,182,000. TD Asset Management Inc bought a new position in shares of Heartflow in the third quarter valued at about $2,692,000. New York State Common Retirement Fund acquired a new position in Heartflow during the 3rd quarter worth about $4,015,000. Artisan Partners Limited Partnership bought a new stake in Heartflow during the 3rd quarter worth about $16,817,000. Finally, JPMorgan Chase & Co. acquired a new stake in Heartflow in the 3rd quarter valued at about $13,887,000.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group reiterated a “buy” rating and set a $40.00 price objective on shares of Heartflow in a research note on Monday. JPMorgan Chase & Co. boosted their target price on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Wells Fargo & Company began coverage on shares of Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, Stifel Nicolaus lifted their price target on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Heartflow presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.